A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
Condition: SmallpoxInterventions: Biological: IMVAMUNE; Biological: IMVAMUNE; Biological: IMVAMUNE; Other: PlaceboSponsor: Bavarian NordicCompleted - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials